• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早老素-1 S170F 突变所致常染色体显性遗传性阿尔茨海默病的表型变异性。

Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1.

机构信息

Department of Neurology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany.

出版信息

Neurodegener Dis. 2018;18(2-3):57-68. doi: 10.1159/000485899. Epub 2018 Feb 22.

DOI:10.1159/000485899
PMID:29466804
Abstract

BACKGROUND

In rare cases, patients with Alzheimer disease (AD) present at an early age and with a family history suggestive of an autosomal dominant mode of inheritance. Mutations of the presenilin-1 (PSEN1) gene are the most common causes of dementia in these patients. Early-onset and particularly familial AD patients frequently present with variable non-amnestic cognitive symptoms such as visual, language or behavioural changes as well as non-cognitive, e.g. motor, symptoms.

OBJECTIVE

To investigate the phenotypic variability in carriers of the PSEN1 S170F mutation.

METHODS

We report a family with 4 patients carrying the S170F mutation of whom 2 underwent detailed clinical examinations. We discuss our current findings in the context of previously reported S170F cases.

RESULTS

The clinical phenotype was consistent regarding initial memory impairment and early onset in the late twenties found in all S170F patients. There were frequent non-amnestic cognitive changes and, at early stages of the disease, indications of a more pronounced disturbance of visuospatial abilities as compared to face and object recognition. Non-cognitive symptoms most often included myoclonus and cerebellar ataxia. A review of the available case reports indicates some phenotypic variability associated with the S170F mutation including different constellations of symptoms such as parkinsonism and delusions.

CONCLUSION

The variable clinical findings associated with the S170F mutation highlight the relevance of atypical phenotypes in the context of research and under a clinical perspective. CSF sampling and detection of Aβ species may be essential to indicate AD pathology in unclear cases presenting with cognitive and motor symptoms at a younger age.

摘要

背景

在极少数情况下,阿尔茨海默病(AD)患者发病年龄较早,且有家族史提示常染色体显性遗传模式。早发型和家族性 AD 患者常出现各种非遗忘性认知症状,如视觉、语言或行为改变,以及非认知症状,如运动症状。

目的

研究载脂蛋白 E 基因 PSEN1 S170F 突变携带者的表型变异性。

方法

我们报告了一个携带 S170F 突变的家族,其中 2 名患者接受了详细的临床检查。我们在以前报道的 S170F 病例的背景下讨论了我们目前的发现。

结果

所有 S170F 患者均存在首发记忆障碍和二十多岁后期的早发性,其临床表型一致。常出现非遗忘性认知改变,在疾病早期,与面孔和物体识别相比,视空间能力的障碍更为明显。非认知症状最常包括肌阵挛和小脑共济失调。对现有病例报告的回顾表明,S170F 突变与一些表型变异性相关,包括帕金森病和妄想等不同症状的组合。

结论

S170F 突变相关的可变临床发现强调了在研究和临床角度下,非典型表型的相关性。CSF 取样和 Aβ 物种的检测对于在出现认知和运动症状的年轻患者中指示 AD 病理可能是必不可少的。

相似文献

1
Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1.早老素-1 S170F 突变所致常染色体显性遗传性阿尔茨海默病的表型变异性。
Neurodegener Dis. 2018;18(2-3):57-68. doi: 10.1159/000485899. Epub 2018 Feb 22.
2
Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.常染色体显性遗传性阿尔茨海默病的临床表型和遗传相关性:病例系列研究。
Lancet Neurol. 2016 Dec;15(13):1326-1335. doi: 10.1016/S1474-4422(16)30193-4. Epub 2016 Oct 21.
3
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life.导致在生命第三个十年出现路易体痴呆症的新型早老素1突变(S170F)。
Arch Neurol. 2005 Dec;62(12):1821-30. doi: 10.1001/archneur.62.12.1821.
4
Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.早老素1基因S170F突变与一种新型阿尔茨海默病分子表型的关联。
Arch Neurol. 2007 May;64(5):738-45. doi: 10.1001/archneur.64.5.738.
5
Pathological manifestation of the induced pluripotent stem cell-derived cortical neurons from an early-onset Alzheimer's disease patient carrying a presenilin-1 mutation (S170F).早发型阿尔茨海默病患者携带早老素-1 突变(S170F)诱导多能干细胞源性皮质神经元的病理表现。
Cell Prolif. 2020 Apr;53(4):e12798. doi: 10.1111/cpr.12798. Epub 2020 Mar 25.
6
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.早发性阿尔茨海默病中APP、PSEN1和PSEN2基因突变:家族性和散发性病例的基因筛查研究
PLoS Med. 2017 Mar 28;14(3):e1002270. doi: 10.1371/journal.pmed.1002270. eCollection 2017 Mar.
7
Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation.早发性家族性阿尔茨海默病患者中早老素-1 E280A 突变的表型谱。
J Alzheimers Dis. 2012;32(1):1-12. doi: 10.3233/JAD-2012-120907.
8
Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain.西班牙早发性阿尔茨海默病中早老素和淀粉样前体蛋白基因突变的频率。
Arch Neurol. 2002 Nov;59(11):1759-63. doi: 10.1001/archneur.59.11.1759.
9
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.迟发性常染色体显性遗传和散发性阿尔茨海默病之间的表型相似性:一项单家族病例对照研究。
JAMA Neurol. 2016 Sep 1;73(9):1125-32. doi: 10.1001/jamaneurol.2016.1236.
10
Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia.一个患有非典型阿尔茨海默病痴呆症的非裔美国家庭中的早老素1突变。
Arch Neurol. 2003 Jun;60(6):884-8. doi: 10.1001/archneur.60.6.884.

引用本文的文献

1
Presenilin-1 (PSEN1) Mutations: Clinical Phenotypes beyond Alzheimer's Disease.早老素 1(PSEN1)突变:阿尔茨海默病以外的临床表型。
Int J Mol Sci. 2023 May 8;24(9):8417. doi: 10.3390/ijms24098417.
2
Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review.治疗性小分子在神经退行性疾病治疗中对细胞凋亡调控的作用:最新综述。
Molecules. 2022 Oct 25;27(21):7207. doi: 10.3390/molecules27217207.
3
Acetylcholine deficiency disrupts extratelencephalic projection neurons in the prefrontal cortex in a mouse model of Alzheimer's disease.
乙酰胆碱缺乏会破坏阿尔茨海默病小鼠模型前额叶皮层的外端脑投射神经元。
Nat Commun. 2022 Feb 22;13(1):998. doi: 10.1038/s41467-022-28493-4.